Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: Involvement of α7 nicotinic receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 315, Issue 2, 2005, Pages 658-667

  Escubedo, Elena ^a   Chipana, Carlos ^a   Pérez Sánchez, Mónica ^a   Camarasa, Jordi ^a   Pubill, David ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BUNGAROTOXIN; CALCIUM; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIHYDRO BETA ERYTHROIDINE; DOPAMINE; METHAMPHETAMINE; METHYLLYCACONITINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NEURONAL NITRIC OXIDE SYNTHASE; NICOTINIC RECEPTOR; PROTEIN KINASE C; PROTEIN SUBUNIT; REACTIVE OXYGEN METABOLITE; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL ACTIVATION; CELL VACUOLE; CLIMBING; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG EFFECT; FLOW CYTOMETRY; HYPERTHERMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SYNAPTOSOME;

ACONITINE; ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; BODY TEMPERATURE; BODY WEIGHT; CALCIUM; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; ENZYME INHIBITORS; IMMUNOHISTOCHEMISTRY; ISOQUINOLINES; MALE; METHAMPHETAMINE; MICE; MICROGLIA; MOTOR ACTIVITY; NEOSTRIATUM; NEUROTOXICITY SYNDROMES; NICOTINIC ANTAGONISTS; RADIOLIGAND ASSAY; REACTIVE OXYGEN SPECIES; RECEPTORS, NICOTINIC; SYNAPTIC VESICLES; SYNAPTOSOMES; TYROSINE 3-MONOOXYGENASE;

EID: 27144518233     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.089748     Document Type: Article

References (40)

1. Bowyer JF, Tank AW, Newport GD, Slikker W Jr, Ali SF, and Holson RR (1992) The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther 260:817-824.
2. 3H]WIN 35,428 binding to the dopamine uptake carrier. I. Effect of tonicity and buffer composition. J Neurosci Methods 51:23-30.
3. Damaj MI, Kao W, and Martin BR (2003) Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J Pharmacol Exp Ther 307:526-534.
4. Davidson C, Gow AJ, Lee TH, and Ellinwood EH (2001) Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev 36:1-22.
5. 3H] methyllycaconitine: a new radioligand for labelling alpha 7-type neuronal nicotinic acetylcholine receptors. Neuropharmacology 38:679-690.
6. Demiryurek AT, Cakici I, and Kanzik I (1998) Peroxynitrite: a putative cytotoxin. Pharmacol Toxicol 82:113-117.
7. Deng X and Cadet JL (1999) Methamphetamine administration causes overexpression of nNOS in the mouse striatum. Brain Res 851:254-257.
8. Drew AE and Werling LL (2001) Protein kinase C regulation of dopamine transporter initiated by nicotinic receptor activation in slices of rat prefrontal cortex. J Neurochem 77:839-848.
9. Ellison G, Eison MS, Huberman HS, and Daniel F (1978) Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration. Science (Wash DC) 201:276-278.
10. Escubedo E, Guitart L, Sureda FX, Jimenez A, Pubill D, Pallas M, Camins A, and Camarasa J (1998) Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Brain Res 814:120-126.
11. Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, and Hanson GR (1997) Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther 282:834-838.
12. Florin SM, Kuczenski R, and Segal DS (1995) Effects of reserpine on extracellular caudate dopamine and hippocampus norepinephrine responses to amphetamine and cocaine: mechanistic and behavioral considerations. J Pharmacol Exp Ther 274:231-241.
13. Gerhardt S, Gerber R, and Liebman JM (1985) SCH 23390 dissociated from conventional neuroleptics in apomorphine climbing and primate acute dyskinesia models. Life Sci 37:2355-2363.
14. Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633-643.
15. Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, and Fleckenstein AE (2002) Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J Pharmacol Exp Ther 300:1093-1100.
16. Hastings TG (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 64:919-924.
17. Hogg RC, Raggenbass M, and Bertrand D (2003) Nicotinic acetylcholine receptors: from structure to brain function. Rev Physiol Biochem Pharmacol 147:1-46.
18. Imam SZ, Newport GD, Islam F, Slikker W Jr, and Ali SF (1999) Selenium, an antioxidant, protects against methamphetamine-induced dopaminergic neurotoxicity. Brain Res 818:575-578.
19. 3H]dopamine release in rat striatal slices via glutamate release. Mol Pharmacol 58:312-318.
20. Larsen KE, Fon EA, Hastings TG, Edwards RH, and Sulzer D (2002) Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci 22:8951-8960.
21. Liu PS, Liaw CT, Lin MK, Shin SH, Kao LS, and Lin LF (2003) Amphetamine enhances Ca2+ entry and catecholamine release via nicotinic receptor activation in bovine adrenal chromaffin cells. Eur J Pharmacol 460:9-17.
22. Ljungberg T and Ungerstedt U (1985) A rapid and simple behavioural screening method for simultaneous assessment of limbic and striatal blocking effects of neuroleptic drugs. Pharmacol Biochem Behav 23:479-485.
23. Matsubayashi H, Inoue A, Amano T, Seki T, Nakata Y, Sasa M, and Sakai N (2004) Involvement of alpha7- and alpha4beta2-type postsynaptic nicotinic acetylcholine receptors in nicotine-induced excitation of dopaminergic neurons in the substantia nigra: a patch clamp and single-cell PCR study using acutely dissociated nigral neurons. Brain Res Mol Brain Res 29:1-7.
24. Mogg AJ, Whiteaker P, McIntosh JM, Marks M, Collins AC, and Wonnacott S (2002) Methyllycaconitine is a potent antagonist of alpha-conotoxin-MII- sensitive presynaptic nicotinic acetylcholine receptors in rat striatum. J Pharmacol Exp Ther 302:197-204.
25. Nordahl TE, Salo R, and Leamon M (2003) Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci 15:317-325.
26. Park SU, Ferrer JV, Javitch JA, and Kuhn DM (2002) Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons. J Neurosci 22:4399-4405.
27. Pifl C, Drobny H, Reither H, Hornykiewicz O, and Singer EA (1995) Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol Pharmacol 47:368-373.
28. Pubill D, Canudas AM, Pallas M, Camins A, Camarasa J, and Escubedo E (2003) Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn-Schmiedeberg's Arch Pharmacol 367:490-499.
29. Pubill D, Chipana C, Camins A, Pallas M, Camarasa J, and Escubedo E (2005) Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicol Appl Pharmacol 204:57-68.
30. Pubill D, Verdaguer E, Sureda FX, Camins A, Pallas M, Camarasa J, and Escubedo E (2002) Carnosine prevents methamphetamine-induced gliosis but not dopamine terminal loss in rats. Eur J Pharmacol 448:165-168.
31. Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, and Moore RY (1982) Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 235:93-103.
32. Sanchez V, Zeini M, Camarero J, O'Shea E, Bosca L, Green AR, and Colado MI (2003) The nNOS inhibitor, AR-R17477AR, prevents the loss of NF68 immunoreactivity induced by methamphetamine in the mouse striatum. J Neurochem 85:515-524.
33. Sandoval V, Riddle EL, Ugarte YV, Hanson GR, and Fleckenstein AE (2001) Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci 21:1413-1419.
34. Sonsalla PK, Nicklas WJ, and Heikkila RE (1989) Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science (Wash DC) 243:398-400.
35. Sonsalla PK, Riordan DE, and Heikkila RE (1991) Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J Pharmacol Exp Ther 256:506-512.
36. Stephenson DT, Schober DA, Smalstig EB, Mincy RE, Gehlert DR, and Clemens JA (1995) Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat. J Neurosci 15:5263-5274.
37. Turek JW, Kang CH, Campbell JE, Arneric SP, and Sullivan JP (1995) A sensitive technique for the detection of the alpha 7 neuronal nicotinic acetylcholine receptor antagonist, methyllycaconitine, in rat plasma and brain. J Neurosci Methods 61:113-118.
38. Vowinckel E, Reutens D, Becher B, Verge G, Evans A, Owens T, and Antel JP (1997) PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res 50:345-353.
39. Ward JM, Cockcroft VB, Lunt GG, Smillie FS, and Wonnacott S (1990) Methyllycaconitine: a selective probe for neuronal alpha-bungarotoxin binding sites. FEBS Lett 270:45-48.
40. Yamamoto BK and Zhu W (1998) The effects of methamphetamine on the production of free radicals and oxidative stress. J Pharmacol Exp Ther 287:107-114.